DOTMA (N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium) is a tetra-methylated DOTA analogue. DOTMA is a cationic lipid and can be used as a non-viral vector for gene therapy.

A-196 is a potent and selective inhibitor of SUV420 h1 and SUV420 h2 with IC50 values of 0.025 and 0.144 μM, respectively.

Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.